BPC-157 + TB-500 5/5 blend

Last verified: 2026-05-01

At a glance


Composition	5 mg BPC-157 + 5 mg TB-500 in a single 10 mg vial
Class	Pre-mixed research-chemical blend; not an FDA-recognised combination
Typical route	Subcutaneous injection (IM possible; oral is BPC-157-only territory and the blend isn’t designed for it)
Typical dose	250–600 mcg total daily, or 1.75–4 mg total weekly across split doses
UK and US status	Not approved as a medicine in any jurisdiction. Sold as a research chemical labelled “not for human consumption.”

What it is

This is a pre-mixed blend containing equal masses of two of the most commonly stacked recovery / repair peptides: 5 mg BPC-157 and 5 mg TB-500 in a single vial. Many research-chemical vendors sell this as a convenience SKU because the two compounds are so frequently combined; the blend ships ready to reconstitute as a single solution rather than reconstituting two vials and drawing into the same syringe.

It is not a separate compound — it’s just BPC-157 and TB-500 sharing a vial. The full pharmacology, evidence base, sensitive-systems framing, and safety considerations are covered in the per-component pages:

BPC-157 — gastric protective pentadecapeptide; tissue repair, gut, vasculature, mast-cell-active in some users
TB-500 — thymosin β4 fragment; actin-binding, soft-tissue and vascular recovery, longer half-life

This page covers only what’s blend-specific: the math, when the convenience matters, and what the equal-mass formulation does and doesn’t change.

When the blend makes sense

The blend is mechanically convenient when:

The user runs both compounds at the same dose and frequency
They want one injection rather than two (or one syringe draw rather than two)
Equal-component dosing is the right choice for the protocol — typically a recovery / orthopaedic phase rather than a sensitive-systems gut-protocol where BPC alone is more appropriate

The blend is not the right choice when:

The user wants to titrate the two compounds independently (e.g. starting BPC at 100 mcg for sensitive-systems tolerance while running TB at full dose)
BPC-only or TB-only use is the actual indication (gut healing → BPC alone; soft-tissue injury → TB-500 carries the bulk of the published evidence; combining is an additional choice)
The user wants different routes or frequencies for the two components

For users in either of those situations, separate vials are better — same compounds, same protocol logic, more flexibility.

The math

The blend is straightforward to plan because both components are at the same mass concentration:

10 mg blend (5 mg BPC + 5 mg TB), 3 mL BAC water (the standard)

Total concentration: 3.33 mg/mL (3,333 mcg/mL total = 1,667 mcg/mL of each component)
250 mcg total = 0.075 mL = 7.5 units (rounds to 7 or 8)
500 mcg total = 0.15 mL = 15 units
600 mcg total = 0.18 mL = 18 units (the most-cited daily dose)

10 mg blend, 2 mL BAC water (denser concentration for higher-dose protocols)

Total concentration: 5 mg/mL (5,000 mcg/mL total)
500 mcg total = 0.1 mL = 10 units
1000 mcg total = 0.2 mL = 20 units

The Peptrax Vial Plan calculator handles both blend-aware presets — dose_basis: total for total-blend dosing, and dose_basis: component for users targeting a specific BPC or TB amount with the other component coming along for the ride.

Storage and stability

Same as the per-component peptides:

Reconstituted with BAC water: ~28 days refrigerated (2–8°C). Conservative end of the spread is 14–21 days; middle is 28; some practitioners run vials longer with no obvious issue.
Reconstituted with plain sterile water: single-use, discard within 24 hours.
Do not freeze. Store at the back of the refrigerator where temperature is most stable.

For 600 mcg/day from a 10 mg blend at 3 mL BAC: ~16 doses → 16 days, comfortably within shelf life.

What the blend doesn’t change

The clinical picture, sensitive-systems framing, sourcing concerns, and safety considerations are the union of the BPC-157 and TB-500 profiles. The per-component pages cover:

Mechanism for each compound
Evidence base (and the genuine evidence gaps for both)
Sensitive-systems profile, including the BPC-157 mast-cell signal that’s relevant for MCAS users
Cancer / IGF-1 / mitogenic concerns where applicable
Route-specific guidance (BPC-157 oral has its own profile; TB-500 is injection-only in practice)
Quality and sourcing caveats common to research-chem peptide markets

Read the BPC-157 and TB-500 pages in full before running the blend.

What to track in Peptrax

The blend is one entry in the app, but the protocol is two compounds — log it that way. If the user is running the blend with the goal of orthopaedic recovery (the dominant use case), the per-week total dose, total weeks on, and the specific tissue / injury rated weekly on the same scale across the cycle is the read that lets the user decide whether the protocol worked. If sensitive-systems tolerability becomes an issue mid-cycle, the right move is usually splitting back into separate vials so BPC and TB can be titrated independently — the blend’s convenience disappears once the two components need different dose schedules.

For personal tracking and informational purposes only — not medical advice.